| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The peptide binds to various metal ions (e.g., Cu2+, Zn2+) through histidine residues (positions 6, 13, 14). It may also interact with lipid membranes but does not form beta-sheets or toxic aggregates. It has low affinity for the Abeta receptors.
|
|---|---|
| ln Vitro |
In cell-free assays, Abeta1-20 does not aggregate or form amyloid fibrils. Thioflavin T (ThT) assays show no fluorescence increase over time. It binds Cu2+ with a dissociation constant of ~10 uM. It can be used to study the metal-binding region of Abeta without complications from aggregation.
|
| ln Vivo |
When injected into the brain, Abeta1-20 does not induce neurodegeneration or cognitive deficits. It is used as a negative control in behavioral studies to confirm that the effects of full-length Abeta are due to the C-terminal region and aggregation.
|
| Enzyme Assay |
ThT aggregation assay: Abeta1-20 (50 uM) in PBS (pH 7.4) is incubated at 37degC for 72 hours with 10 uM ThT. Fluorescence (Ex/Em 440/480 nm) is measured every 30 minutes. No increase above baseline is observed. For metal binding, isothermal titration calorimetry (ITC) or fluorescence quenching can be used.
|
| Cell Assay |
Primary neurons or SH-SY5Y cells are treated with Abeta1-20 (1-50 uM) for 24-72 hours. Cell viability by MTT or LDH assays shows no toxicity. This peptide serves as a specificity control for studies of Abeta toxicity, confirming that the effects of Abeta1-42 are not due to the N-terminal region.
|
| Animal Protocol |
For behavioral control, Abeta1-20 (5-10 ug in 2-5 uL PBS) is injected ICV into mice. After 1-4 weeks, animals are tested in Morris water maze. No spatial memory impairment is observed, in contrast to Abeta1-42. It is used to rule out non-specific injection effects.
|
| ADME/Pharmacokinetics |
PK: After ICV injection, Abeta1-20 is rapidly cleared from the brain (half-life ~20-40 minutes) via enzymatic degradation (neprilysin, insulin-degrading enzyme). It does not accumulate. Formulation in sterile PBS or saline, often with 0.1% BSA to prevent adsorption.
|
| Toxicity/Toxicokinetics |
Toxicity: Abeta1-20 is non-toxic at experimental concentrations (up to 50 uM in vitro, up to 50 ug ICV in vivo). No adverse effects are reported. Standard peptide handling: store lyophilized at -20degC, avoid repeated freeze-thaw.
|
| References | |
| Additional Infomation |
Abeta1-20 is a useful research tool for studying the metal-binding properties and N-terminal structure of amyloid-beta. The acetate salt form is often used to improve solubility. This peptide is not amyloidogenic and is used as a negative control in Alzheimer‘s disease research. This product is for research use only.
|
| Molecular Formula |
C115H161N31O34
|
|---|---|
| Molecular Weight |
2521.70
|
| Related CAS # |
β-Amyloid (1-20);186319-68-6
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3966 mL | 1.9828 mL | 3.9656 mL | |
| 5 mM | 0.0793 mL | 0.3966 mL | 0.7931 mL | |
| 10 mM | 0.0397 mL | 0.1983 mL | 0.3966 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
